Unlock instant, AI-driven research and patent intelligence for your innovation.

Thyroid hormone receptor beta agonist compounds

A technology of compounds and tautomers, applied in the direction of drug combination, organic chemistry, organic active ingredients, etc., can solve problems such as bone mineral density reduction

Pending Publication Date: 2022-04-19
TERNS PHARMA INC
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Additionally, increased bone turnover has also been noted leading to decreased bone mineral density

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Thyroid hormone receptor beta agonist compounds
  • Thyroid hormone receptor beta agonist compounds
  • Thyroid hormone receptor beta agonist compounds

Examples

Experimental program
Comparison scheme
Effect test

example

[0168] It should be understood that the present disclosure is made by way of example only, and that those skilled in the art may make various changes in the combination and arrangement of parts without departing from the spirit and scope of the present disclosure.

[0169] The chemical reactions in the examples can be readily adapted to prepare a variety of other compounds disclosed herein, and alternative methods for preparing the disclosed compounds are considered to be within the scope of the disclosure. Modifications that are apparent to those skilled in the art are possible, for example, by suitably protecting interfering groups, by utilizing other suitable reagents other than those described in the art, or by routinely altering the reaction conditions , reagents and starting materials to successfully synthesize unexemplified compounds according to the present disclosure. Alternatively, other reactions disclosed herein or known in the art will be considered suitable for p...

example S1

[0186] Example S1: Synthesis of N-(3,5-dichloro-4-((4-oxo-3,4-dihydrophthalazin-1-yl)oxy)phenyl)-5-oxo-4, 5-Dihydro-1,2,4-oxadiazole-3-carboxamide

[0187]

[0188] Synthesis of 3,5-dichloro-4-((4-chlorophthalazin-1-yl)oxy)aniline (1a). To 1,4-dichlorophthalazine (100g, 502.4mmol) and 4-amino- To a solution of 2,6-dichlorophenol (107.3 g, 602.9 mmol) in DMSO (1.0 L) was added Cs 2 CO 3 (196.4 g, 602.9 mmol). The mixture was then stirred at 80°C for 1 hour. TLC and LCMS showed the reaction was complete. The mixture was cooled to 20 °C and added to HCl solution (2M, 7.5 L). The mixture was then filtered to collect solids. H for solid 2 O (800 mL*3) was washed and dried in vacuo to afford 1a. For [M+1] + (C 14 h 8 Cl 3 N 3 O) Calculated MS mass requires m / z 340.0, LCMS experimental value m / z 340.0; 1 H NMR (400MHz, DMSO-d 6 )δ8.46-8.55 (m, 1H), 8.30-8.35 (m, 1H), 8.20-8.29 (m, 2H), 6.78 (s, 2H).

[0189] Synthesis of 4-(4-amino-2,6-dichloro-phenoxy)-2H-phthalaz...

example S2

[0191] Example S2: Synthesis of N-(3,5-dichloro-4-((3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)oxy)phenyl)-5- Oxo-4,5-dihydro-1,2,4-oxadiazole-3-carboxamide

[0192]

[0193]Synthesis of 2-(3,5-dichloro-4-((4-oxo-3,4-dihydrophthalazin-1-yl)oxy)phenyl)isoindoline-1,3-dione (2a). To a solution of 4-(4-amino-2,6-dichloro-phenoxy)-2H-phthalazin-1-one (1b) (500 mg, 1.55 mmol) in AcOH (10 mL) was added Isobenzofuran-1,3-dione (252.88 mg, 1.71 mmol). The mixture was stirred at 120°C for 3 hours. TLC and LCMS showed the reaction was complete. The reaction mixture was diluted with water (30 mL) and filtered to give a cake pad. The cake pad was dried under reduced pressure to afford crude material 2a. The crude product was used directly in the next step. For [M+1] + (C 22 h 11 Cl 2 N 3 o 4 ) calculated MS mass requires m / z 452.0, LCMS experimental value m / z 452.0; 1 H NMR (400MHz, DMSO-d 6 )δ12.06-12.03(m,1H),8.36-8.25(m,3H),8.14-8.09(m,1H),8.07-8.02(m,3H),7.99-7.94(m,2H...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein are compounds, preferably thyroid hormone receptor beta (THRbeta) agonist compounds, compositions and methods of making the same, as well as methods of agonizing THRbeta and methods of treating THRbeta mediated disorders.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Application No. 62 / 899,581, filed September 12, 2019, the contents of which are hereby incorporated by reference in their entirety. technical field [0003] The present invention relates to compounds, preferably thyroid hormone receptor beta (THRβ) agonist compounds, compositions thereof and methods for their preparation, methods of agonizing THRβ and methods of treating disorders mediated by THRβ. Background technique [0004] The beneficial effects of treating hyperthyroid or hypothyroid patients with T3 / T4 endogenous ligands or early analogs of these endogenous ligands have been described in the literature (Richardson Hill Jr., S. (Richardson Hill Jr. , S.) et al., J. Clin. Invest. 1960, 39, 523-533). These early studies, and similar follow-up studies, established the heart as the major organ presenting side effects of hyperthyroidism and hypothyroidism (Klein, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/501A61P5/14C07D237/14C07D403/12
CPCA61P5/14C07D413/12
Inventor T·A·基尔施伯格R·哈尔康卜徐英姿F·A·罗曼罗
Owner TERNS PHARMA INC